Evidence map›Paper›PMID 28127659›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2017

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

Carmel Jacobs, Mark Clemons, Sasha Mazzarello, Brian Hutton, Anil A Joy, Muriel Brackstone, Orit Freedman, Lisa Vandermeer, Mohammed Ibrahim, Dean Fergusson and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02688803 (Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02688803 phase4terminatednot on this map

Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) OTT 15-04

TypeinterventionalSponsorOttawa Hospital Research InstituteRan2016 to 2017Enrolled2ConditionsBreast CancerArmsDose dense AC-P, Dose dense AC, FEC-D
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.Journal of experimental & clinical cancer research : CR · 2019
    Article
  5. Article
  6. Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Carmel JacobsPublic Health and Preventative Medicine, University of Ottawa School of Epidemiology, Ottawa, Canada.
Mark ClemonsDivision of Medical Oncology and Department of Medicine, University of Ottawa, Ottawa, Canada.
Sasha MazzarelloThe Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
Brian HuttonPublic Health and Preventative Medicine, University of Ottawa School of Epidemiology, Ottawa, Canada.
Anil A JoyDivision of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada.
Muriel BrackstoneLondon Health Sciences Centre, London, Canada.
Orit FreedmanDurham Regional Cancer Centre, Oshawa, Canada.
Lisa VandermeerThe Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
Mohammed IbrahimDivision of Medical Oncology and Department of Medicine, University of Ottawa, Ottawa, Canada.
Dean FergussonThe Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
John HiltonDivision of Medical Oncology and Department of Medicine, University of Ottawa, Ottawa, Canada. jfhilton@toh.ca.
Ottawa Hospital Research InstituteUniversity of Ottawa · CALondon Health Sciences Centre · CARegional Municipality of Durham · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe optimal chemotherapy regimen for patients with early stage triple-negative breast cancer (TNBC) remains unknown. The purpose of the study is to survey physicians and breast cancer patients about preferred chemotherapy regimens for early stage TNBC and clinical trial strategies.

methodsA standardised online questionnaire was developed and circulated to medical oncologists known to treat breast cancer. A separate questionnaire was given to patients who had received chemotherapy for breast cancer.

resultsThe questionnaire was completed by 41/84 medical oncologists (48.8% response rate) and 74 patients. The most commonly used neoadjuvant and adjuvant chemotherapy regimens for TNBC were dose-dense doxorubicin and cyclophosphamide (AC)-paclitaxel (P), dose-dense AC followed by weekly P and fluorouracil, epirubicin, cyclophosphamide-docetaxel (FEC-D). The majority of medical oncologists (80%) would be willing to enrol patients in trials evaluating the most effective chemotherapy regimen for TNBC. Oncologists favoured a three arm trial design comparing currently available standard of care treatments (36%) and trials of novel or non-standard of care agents 22% (9/41). Sixty percent (41/74) of patients indicated that they would be willing to be enrolled in trials evaluating various adjuvant regimens for TNBC. Both oncologists and patients were interested in novel consent approaches such as using the integrated consent model.

conclusionOptimisation of chemotherapy for TNBC is an important and unmet clinical need. It is apparent that various chemotherapy regimens are used for patients with early stage TNBC. The majority of medical oncologists and patients are interested in entering trials to optimise chemotherapy choices.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleHumansMiddle AgedPatientsPhysiciansSurveys and QuestionnairesTriple Negative Breast NeoplasmsBreast cancerChemotherapyTrial designTriple negative

Identifiers

PMID28127659
OpenAlexW2580983514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.